JP2020534812A - 改良された相同組換えおよびその組成物のための方法 - Google Patents

改良された相同組換えおよびその組成物のための方法 Download PDF

Info

Publication number
JP2020534812A
JP2020534812A JP2020513724A JP2020513724A JP2020534812A JP 2020534812 A JP2020534812 A JP 2020534812A JP 2020513724 A JP2020513724 A JP 2020513724A JP 2020513724 A JP2020513724 A JP 2020513724A JP 2020534812 A JP2020534812 A JP 2020534812A
Authority
JP
Japan
Prior art keywords
nucleic acid
protein
dna
regulatory
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020513724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534812A5 (https=
Inventor
シークアン リャン
シークアン リャン
ロバート ポッター
ロバート ポッター
ランシャ ポン
ランシャ ポン
Original Assignee
ライフ テクノロジーズ コーポレイション
ライフ テクノロジーズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライフ テクノロジーズ コーポレイション, ライフ テクノロジーズ コーポレイション filed Critical ライフ テクノロジーズ コーポレイション
Publication of JP2020534812A publication Critical patent/JP2020534812A/ja
Publication of JP2020534812A5 publication Critical patent/JP2020534812A5/ja
Priority to JP2023145587A priority Critical patent/JP2023168355A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/95—Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2020513724A 2017-09-08 2018-09-07 改良された相同組換えおよびその組成物のための方法 Pending JP2020534812A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023145587A JP2023168355A (ja) 2017-09-08 2023-09-07 改良された相同組換えおよびその組成物のための方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762555862P 2017-09-08 2017-09-08
US62/555,862 2017-09-08
US201762568661P 2017-10-05 2017-10-05
US62/568,661 2017-10-05
US201762574936P 2017-10-20 2017-10-20
US62/574,936 2017-10-20
US201862626792P 2018-02-06 2018-02-06
US62/626,792 2018-02-06
US201862717403P 2018-08-10 2018-08-10
US62/717,403 2018-08-10
PCT/US2018/049966 WO2019051237A1 (en) 2017-09-08 2018-09-07 ENHANCED RECOMBINANT RECOMBINATION METHODS AND COMPOSITIONS THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023145587A Division JP2023168355A (ja) 2017-09-08 2023-09-07 改良された相同組換えおよびその組成物のための方法

Publications (2)

Publication Number Publication Date
JP2020534812A true JP2020534812A (ja) 2020-12-03
JP2020534812A5 JP2020534812A5 (https=) 2021-10-14

Family

ID=63714051

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513724A Pending JP2020534812A (ja) 2017-09-08 2018-09-07 改良された相同組換えおよびその組成物のための方法
JP2023145587A Pending JP2023168355A (ja) 2017-09-08 2023-09-07 改良された相同組換えおよびその組成物のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023145587A Pending JP2023168355A (ja) 2017-09-08 2023-09-07 改良された相同組換えおよびその組成物のための方法

Country Status (5)

Country Link
US (2) US20190119701A1 (https=)
EP (1) EP3679143A1 (https=)
JP (2) JP2020534812A (https=)
CN (2) CN119570864A (https=)
WO (1) WO2019051237A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
ES2817973T3 (es) 2016-07-01 2021-04-08 Microsoft Technology Licensing Llc Almacenamiento a través de la edición iterativa del ADN
US20180004537A1 (en) 2016-07-01 2018-01-04 Microsoft Technology Licensing, Llc Molecular State Machines
US11359234B2 (en) 2016-07-01 2022-06-14 Microsoft Technology Licensing, Llc Barcoding sequences for identification of gene expression
EP3679143A1 (en) 2017-09-08 2020-07-15 Life Technologies Corporation Methods for improved homologous recombination and compositions thereof
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
EP3781677A4 (en) * 2018-04-16 2022-01-19 University of Massachusetts COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITTING
US12312584B2 (en) * 2018-10-02 2025-05-27 Exosome Therapeutics, Inc. cGMP exosome loaded therapeutics for treating sickle cell disease
US20200102563A1 (en) * 2018-10-02 2020-04-02 Exosome Therapeutics, Inc. Exosome loaded therapeutics for treating sickle cell disease
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
CN111304248B (zh) * 2018-12-25 2021-08-24 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il15基因改造非人动物的构建方法及应用
WO2020159470A1 (en) * 2019-01-28 2020-08-06 Mayo Foundation For Medical Education And Research Mitochondrial genome editing methods
JP7250950B2 (ja) 2019-03-29 2023-04-03 エフ． ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットを標的指向組込みすることによってＦｃＲｎ発現細胞を作製するための方法
AU2020256225B9 (en) * 2019-04-03 2025-04-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
WO2020214610A1 (en) * 2019-04-16 2020-10-22 Arizona Board Of Regents On Behalf Of Arizona State University Cas9 fusion proteins and related methods
US20220348912A1 (en) * 2019-06-20 2022-11-03 University Of Massachusetts Compositions and methods for improved gene editing
CA3144106A1 (en) 2019-07-03 2021-01-07 Integrated Dna Technologies, Inc. Identification, characterization, and quantitation of crispr-introduced double-stranded dna break repairs
US20210079387A1 (en) * 2019-08-27 2021-03-18 The Jackson Laboratory Cleavage-resistant donor nucleic acids and methods of use
US20220275400A1 (en) * 2019-08-30 2022-09-01 The Trustees Of Columbia University In The City Of New York Methods for scalable gene insertions
CN119193713A (zh) * 2019-10-24 2024-12-27 合成Dna技术公司 修饰的双链供体模板
US20230086199A1 (en) * 2019-11-26 2023-03-23 The Broad Institute, Inc. Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
WO2022214522A2 (en) * 2021-04-07 2022-10-13 Astrazeneca Ab Compositions and methods for site-specific modification
EP4083227A1 (en) * 2021-04-29 2022-11-02 4basebio, S.L.U. Linear dna with enhanced resistance against exonucleases
AU2022343268A1 (en) 2021-09-08 2024-03-28 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
CN115029277B (zh) * 2022-06-24 2023-08-22 四川省烟草公司凉山州公司 一株耐酸抗青枯病的假蕈状芽孢杆菌
US20260103695A1 (en) * 2024-02-06 2026-04-16 Integrated Dna Technologies, Inc. Optimized SPCAS9 Proteins for Efficient Genome Editing in Eukaryotic Cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001517939A (ja) * 1997-03-14 2001-10-09 ライフ テクノロジーズ，インコーポレイテッド ペプチドによって増強されるトランスフェクション
US20140315985A1 (en) * 2013-03-14 2014-10-23 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
JP2016509063A (ja) * 2013-02-25 2016-03-24 サンガモ バイオサイエンシーズ， インコーポレイテッド ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物
JP2016515401A (ja) * 2013-04-16 2016-05-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ラットゲノムの標的改変
JP2016539655A (ja) * 2013-12-11 2016-12-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
WO2017066707A1 (en) * 2015-10-14 2017-04-20 Life Technologies Corporation Ribonucleoprotein transfection agents

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5334575A (en) 1992-12-17 1994-08-02 Eastman Kodak Company Dye-containing beads for laser-induced thermal dye transfer
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5888795A (en) 1997-09-09 1999-03-30 Becton, Dickinson And Company Thermostable uracil DNA glycosylase and methods of use
WO2003012036A2 (en) 2001-07-27 2003-02-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Systems for in vivo site-directed mutagenesis using oligonucleotides
HUE030493T2 (en) 2003-04-04 2017-05-29 Basf Enzymes Llc Pectate lyases, nucleic acids and processes encoding them for their production and use
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
CA2720903C (en) 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
US20120329067A1 (en) 2010-01-22 2012-12-27 Barbas Iii Carlos F Methods of Generating Zinc Finger Nucleases Having Altered Activity
EP2660318A1 (en) 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
ES2388020B1 (es) * 2011-03-10 2013-10-01 Universitat De Girona Proteínas recombinantes con efecto antitumoral.
WO2012168307A2 (en) * 2011-06-07 2012-12-13 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Improved recombination efficiency by inhibition of nhej dna repair
WO2013152220A2 (en) 2012-04-04 2013-10-10 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
EP2840140B2 (en) * 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
DK2931891T3 (da) 2012-12-17 2019-08-19 Harvard College Rna-styret modificering af menneskelige genomer
WO2014102688A1 (en) 2012-12-27 2014-07-03 Cellectis New design matrix for improvement of homology-directed gene targeting
US9902973B2 (en) 2013-04-11 2018-02-27 Caribou Biosciences, Inc. Methods of modifying a target nucleic acid with an argonaute
EP2796558A1 (en) 2013-04-23 2014-10-29 Rheinische Friedrich-Wilhelms-Universität Bonn Improved gene targeting and nucleic acid carrier molecule, in particular for use in plants
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
US10787684B2 (en) * 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
EP3470089A1 (en) * 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
EP3083958B1 (en) * 2013-12-19 2019-04-17 Amyris, Inc. Methods for genomic integration
HRP20200529T1 (hr) * 2014-06-06 2020-09-04 Regeneron Pharmaceuticals, Inc. Postupci i pripravci za modificiranje ciljnog lokusa
SG11201701245QA (en) * 2014-08-27 2017-03-30 Caribou Biosciences Inc Methods for increasing cas9-mediated engineering efficiency
EP3201340B1 (en) 2014-10-01 2020-12-02 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
US9879283B2 (en) 2014-10-09 2018-01-30 Life Technologies Corporation CRISPR oligonucleotides and gene editing
WO2016065364A1 (en) 2014-10-24 2016-04-28 Life Technologies Corporation Compositions and methods for enhancing homologous recombination
EP4464338A3 (en) 2014-11-07 2025-02-12 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
US10190106B2 (en) * 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
CN118271422A (zh) * 2015-08-28 2024-07-02 分子传递有限公司 转染络合物和其使用方法
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
CA2947904A1 (en) 2015-11-12 2017-05-12 Pfizer Inc. Tissue-specific genome engineering using crispr-cas9
WO2017096041A1 (en) 2015-12-02 2017-06-08 The Regents Of The University Of California Compositions and methods for modifying a target nucleic acid
EP3423438A4 (en) * 2016-03-01 2020-05-06 Molecular Transfer, Inc. PLANT VIRUS MOTOR PROTEINS AND METHOD FOR USE THEREOF
US10428327B2 (en) 2016-05-27 2019-10-01 Life Technologies Corporation Compositions and methods for enhancing homologous recombination
EP4321623A3 (en) * 2016-07-15 2024-05-15 Salk Institute for Biological Studies Methods and compositions for genome editing in non-dividing cells
EP3679144A1 (en) * 2017-09-08 2020-07-15 Life Technologies Corporation Methods for improved homologous recombination and compositions thereof
EP3679143A1 (en) 2017-09-08 2020-07-15 Life Technologies Corporation Methods for improved homologous recombination and compositions thereof
EP3688159A4 (en) * 2017-09-26 2021-10-20 The Board of Trustees of the University of Illinois CRISPR / CAS SYSTEM AND PROCESS FOR GENOME EDITING AND TRANSCRIPT MODULATION

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001517939A (ja) * 1997-03-14 2001-10-09 ライフ テクノロジーズ，インコーポレイテッド ペプチドによって増強されるトランスフェクション
JP2016509063A (ja) * 2013-02-25 2016-03-24 サンガモ バイオサイエンシーズ， インコーポレイテッド ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物
US20140315985A1 (en) * 2013-03-14 2014-10-23 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
JP2016515401A (ja) * 2013-04-16 2016-05-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ラットゲノムの標的改変
JP2016539655A (ja) * 2013-12-11 2016-12-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
WO2017066707A1 (en) * 2015-10-14 2017-04-20 Life Technologies Corporation Ribonucleoprotein transfection agents

Also Published As

Publication number Publication date
CN119570864A (zh) 2025-03-07
US20190119701A1 (en) 2019-04-25
US20240247286A1 (en) 2024-07-25
CN111315889A (zh) 2020-06-19
EP3679143A1 (en) 2020-07-15
WO2019051237A1 (en) 2019-03-14
US12612650B2 (en) 2026-04-28
JP2023168355A (ja) 2023-11-24

Similar Documents

Publication Publication Date Title
US12612650B2 (en) Methods for improved homologous recombination and compositions thereof
US20240247262A1 (en) Crispr/cas system and method for genome editing and modulating transcription
JP7220737B2 (ja) 標的ゲノム修飾を増強するためのプログラム可能なｄｎａ結合タンパク質の使用
JP7559005B2 (ja) 真核ゲノム修飾のための操作されたＣａｓ９システム
US20250154531A1 (en) Methods for improved homologous recombination and compositions thereof
ES2901629T3 (es) Uso de dominios de proteínas de interacción con el nucleosoma para mejorar la modificación dirigida del genoma
KR102004076B1 (ko) 3-성분 crispr/cas 복합체 시스템 및 그 용도
CN109415729B (zh) 具有降低毒性的基因编辑试剂
JP2020530992A (ja) Ｃｒｉｓｐｒ／ｃａｓアクチベーターシステムのための合成ガイドｒｎａ
JP2016523084A (ja) 標的組込み
WO2017107898A2 (en) Compositions and methods for gene editing
US20230128316A1 (en) Hairpin loop ended self-complementary double-stranded covalently closed linear dna vector, manufacturing system and process, and uses of said resulting dna vector
HK40027119A (en) Methods for improved homologous recombination and compositions thereof
HK40029778A (en) Methods for improved homologous recombination and compositions thereof
HK40093157A (zh) 使用可编程dna结合蛋白增强靶向基因组修饰
EA048319B1 (ru) СКОНСТРУИРОВАННЫЕ СИСТЕМЫ CasX
HK40040051A (en) Engineered cas9 systems for eukaryotic genome modification

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231018

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260304